Eye Med Distributor's $100M Suit Barred By Deal, Akorn Says

Law360, New York (January 28, 2013, 3:36 PM EST) -- Generic-drug maker Akorn Inc. on Friday asked a New York federal court to dismiss most claims from Fera Pharmaceuticals LLC’s $100 million suit accusing it of trade secrets theft, breach of a supply agreement and unfair competition, arguing the allegations were invalid or barred by the agreement.

According to Akorn’s motion to dismiss, the distributor’s accusations are essentially revenge for Akorn's termination of the supply agreement after Fera failed to make required contractual minimum purchases, and are not based on any rights within the contract....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

FERA Pharmaceuticals, LLC v. Akorn, Inc. et al


Case Number

1:12-cv-07694

Court

New York Southern

Nature of Suit

Contract: Other

Judge

Louis L. Stanton

Date Filed

October 15, 2012

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.